Merck, known as MSD outside the United States and Canada, announced today that it is has completed its acquisition of Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products, for $…
Author: The Medical News
pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIE…
Inspire reports net loss of $17.6 million for first quarter 2011
Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or per common share, as compared to a net loss of $14.8 million, or per common share, for the same period …
Mary Ann Liebert’s peer-reviewed journal highlights latest developments in ocular gene therapy
Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body.
Kowa presents three K-115 study results against glaucoma at ARVO 2011
Kowa Company Ltd, today announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension.
Study shows benefits and safety of pediatric contact lens wear
After ten years of contact lens wear, patients are equally successful wearing contact lenses whether they were first fitted as children or as teenagers, new research shows.
Study examines community-based HIV testing programs in Africa, Southeast Asia
If you want to improve HIV testing rates in remote rural areas, get the community involved, says UCLA’s Thomas Coates, who has directed a new study examining HIV testing programs in communities in Africa and Southeast Asia.
Study demonstrates value of MicroPulse technology for diabetic macular edema treatment
IRIDEX Corporation today announced that leading clinicians have performed and published the results of a new study that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the …
Research experts to speak at brain tumor educational conference
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
MiMedx introduces AmnioFix Nerve Wrap for use in surgical procedures
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix Nerve Wrap, the Company’s latest biolog…
SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related fun…
Retina Implant’s second clinical trial initial findings presented at ARVO 2011
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the presentation of initial findings from their second clinical trial.
Merck’s Phase III study shows efficacy results of tafluprost to treat ocular hypertension
Merck, known as MSD outside the United States and Canada, announced today that new Phase III data showed that patients with open-angle glaucoma or ocular hypertension, who were dosed once-daily with tafluprost, Merck’s investigational, preservative-fre…
ARVO announces 2011 award recipients in retinal research
The Association for Research in Vision and Ophthalmology is pleased to announce its 2011 ARVO Award recipients. These award recipients will be acknowledged at the ARVO 2011 Annual Meeting, May 1 – 5, in Fort Lauderdale, Fla.
Merck first quarter sales increase 1% to $11.6 billion for 2011
Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.
ARVO announces 2011 distinguished fellows in ophthalmology research
The Association for Research in Vision and Ophthalmology is pleased to announce this year’s class of distinguished fellows. The title of Fellow of ARVO recognizes members for their accomplishments, leadership and contributions to the Association.
LSI announces publication of Emerging Medtech Companies report
Life Science Intelligence, a leading medical technology market intelligence firm, has announced the publication of its Report on Emerging Medtech Companies in Q1 2011.
Gene therapy approach using CD59 shows promise against AMD: Study
A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.
Avastin, Lucentis are equally effective for age-related macular degeneration treatment
Age-related macular degeneration, a disease that damages the retina and can destroy central vision, affects approximately 1.6 million Americans. For the past five years, there has been active debate over treatment options for AMD patients because ophth…
Merck, Inspire announce expiration of HSR waiting period for cash tender offer
Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”) has expired in connection with the pr…